Cochrane · systematic review · CD001500
Local oestrogen for vaginal atrophy in postmenopausal women
Lethaby, A, Ayeleke, RO, Roberts, H · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
Gynaecology and FertilityAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
18
current version
GRADE rated
17
No studies
1
Included studies
NR
No studies 1 · 5.6%Ungraded 0 · 0%Very low 0 · 0%Low 15 · 83.3%Moderate 2 · 11.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Oestrogen ring compared to other regimens for vaginal atrophy in postmenopausal women
Population: postmenopausal women with vaginal atrophy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Improvement in symptoms (participant‐assessed) (oestrogen ring vs oestrogen cream) Oestrogen ring vs other regimens | OR 1.33 [0.8, 2.19] | 2 studies · 341 participants | Low Downgraded: risk of bias, imprecision |
Improvement in symptoms (participant‐assessed) (oestrogen ring vs oestrogen tablets) Oestrogen ring vs other regimens | OR 0.78 [0.53, 1.15] | 3 studies · 567 participants | Low Downgraded: risk of bias, imprecision |
Endometrial thickness (oestrogen ring vs oestrogen cream) Oestrogen ring vs other regimens | OR 0.36 [0.14, 0.94] | 2 studies · 273 participants | Low Downgraded: risk of bias, imprecision |
Improvement in symptoms (clinician‐assessed) (oestrogen ring vs oestrogen cream) Oestrogen ring vs other regimens | OR 1.04 [0.7, 1.53] | 3 studies · 533 participants | Low Downgraded: risk of bias, imprecision |
Improvement in symptoms (clinician‐assessed) (oestrogen ring vs oestrogen tablets) Oestrogen ring vs other regimens | OR 1.45 [0.9, 2.32] | 2 studies · 397 participants | Low Downgraded: risk of bias, imprecision |
Adverse events (total adverse events) (oestrogen ring vs oestrogen cream) Oestrogen ring vs other regimens | OR 0.88 [0.47, 1.63] | 1 study · 192 participants | Low Downgraded: imprecision |
Adverse events (total adverse events) (oestrogen ring vs placebo) Oestrogen ring vs other regimens | OR 0.45 [0.11, 1.78] | 1 study · 37 participants | Moderate Downgraded: imprecision |
Oestrogen tablets compared to other regimens for vaginal atrophy in postmenopausal women
Population: postmenopausal women with vaginal atrophy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Improvement in symptoms (participant‐assessed) (oestrogen tablets vs oestrogen cream) Oestrogen tablets vs other regimens | OR 1.06 [0.55, 2.01] | 2 studies · 208 participants | Low Downgraded: imprecision |
Improvement in symptoms (participant‐assessed) (oestrogen tablets vs placebo) Oestrogen tablets vs other regimens | OR 12.47 [9.81, 15.84] | 2 studies · 1638 participants | Low Downgraded: risk of bias, inconsistency |
Endometrial thickness (oestrogen tablets vs oestrogen cream) Oestrogen tablets vs other regimens | OR 0.31 [0.06, 1.6] | 2 studies · 151 participants | Low Downgraded: imprecision |
Improvement in symptoms (clinician‐assessed) (oestrogen tablets vs oestrogen cream) Oestrogen tablets vs other regimens | OR 1.03 [0.7, 1.52] | 3 studies · 528 participants | Low Downgraded: risk of bias, imprecision |
Improvement in symptoms (clinician‐assessed) (oestrogen tablets vs placebo) Oestrogen tablets vs other regimens | OR 12.85 [10.39, 15.89] | 4 studies · 2078 participants | Low Downgraded: risk of bias, inconsistency |
Adverse events (total adverse events) (oestrogen tablets vs placebo) Oestrogen tablets vs other regimens | OR 1.27 [0.24, 6.69] | 1 study · 309 participants | Moderate Downgraded: imprecision |
Oestrogen cream compared to other regimens for vaginal atrophy in postmenopausal women
Population: postmenopausal women with vaginal atrophy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Improvement in symptoms (participant‐assessed) (oestrogen cream vs isoflavone gel) Oestrogen cream vs other regimens | OR 2.08 [0.08, 53.76] | 1 study · 50 participants | Low Downgraded: imprecision |
Improvement in symptoms (participant‐assessed) oestrogen cream vs placebo) Oestrogen cream vs other regimens | OR 4.1 [1.88, 8.93] | 2 studies · 198 participants | Low Downgraded: risk of bias, imprecision |
Endometrial thickness not reported Oestrogen cream vs other regimens | no estimate extracted | NR | No studies |
Improvement in symptoms (clinician‐assessed) (oestrogen cream vs placebo) Oestrogen cream vs other regimens | OR 3.29 [1.47, 7.36] | 1 study · 153 participants | Low Downgraded: risk of bias, imprecision |
Adverse events (total adverse events) (oestrogen cream vs non‐hormonal lubricant gel) Oestrogen cream vs other regimens | OR 10.67 [0.54, 209.64] | 1 study · 50 participants | Low Downgraded: imprecision |